NewTimeSpace News: Nanjing Leads Biolabs Co., Ltd. (09887.HK) announced that the first patient dosing has been completed in the Phase Ib/II clinical trial of its core product Velixin™ (LBL-024) for the treatment of relapsed or metastatic triple-negative breast cancer, marking new progress in the development of this drug for breast cancer indications.
NewTimeSpace News: POP MART (09992.HK) has released a business update announcement, stating that the total global sales volume of products under all its IPs surpassed 400 million units in 2025. Among them, the core IP "THE MONSTERS" achieved annual global sales of over 100 million units, serving as a crucial sales pillar.
NewTimeSpace News, CGS announced on February 9 the successful issuance of the 4th Tranche of Short-Term Financing Bonds in 2026, with an issuance scale of RMB 4 billion and a final coupon rate of 1.67%. All the funds raised will be used exclusively to supplement the company's working capital.
NewTimeSpace News, CHINA WATER announced on February 9 that its wholly-owned subsidiary Yinlong has entered into a framework agreement with the joint venture company to renew the continuing connected transactions. The joint venture company will supply equipment and services related to pipeline direct drinking water to China Water Affairs Group from April 1, 2026 to March 31, 2029, with an annual transaction cap of RMB 40 million for each year.
NewTimeSpace News, JIUYUAN GENE announced on February 9 that the Investigational New Drug (IND) application for JY54 Injection, a self-developed Class 1 chemical innovative drug, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. The drug is focused on weight management for obese or overweight populations and has demonstrated excellent preclinical data.
NewTimeSpace News: Peijia Medical Limited (09996.HK) announced on February 9, 2026 that the company has recently officially submitted the EU MDR CE mark registration application for its self-developed GeminiOne® Transcatheter Edge-to-Edge Repair System for the treatment of mitral regurgitation, marking progress in the product's global strategic layout. The registration application for the product in China has also been accepted, and it has obtained approval from the US FDA to initiate early clinical studies.
NewTimeSpace News: Butong Group Limited (06090.HK) announced that the trustee of its share incentive plan purchased a total of 50,000 existing shares on the market on February 6, 2026, with a total consideration of approximately HK$4.8087 million and an average price of approximately HK$96.17 per share.
NewTimeSpace News, ELATE HOLDINGS announced on February 6 that it has signed a three-year cooperation and management agreement with Aomi Company, a leading local lifestyle e-commerce platform in Macau. Under the agreement, Elate Holdings will assist Aomi Company in expanding into Asian markets, participating in internal management, and introducing artificial intelligence technology. The two parties will subsequently sign a further agreement to clarify details regarding management fees and profit-sharing.
NewTimeSpace News, SKB BIO-B announced on February 6 that its core product TROP2 ADC sacituzumab govitecan (sac-TMT) has obtained approval from the National Medical Products Administration (NMPA) for the launch of its fourth indication, targeting the treatment of a specific type of HR+/HER2- breast cancer.
NewTimeSpace News, CM-ENERGY announced on February 6 that based on preliminary review, its 2025 revenue is expected to decrease by 17%-20% year-on-year, and the net profit attributable to the company's owners is projected to plunge 80%-90% year-on-year. The main reasons are the reduction in orders for offshore engineering equipment and the delayed progress of the Mexican onshore drilling rig upgrade project.
On February 4, 2026, affected by the sell-off in software stocks triggered by overseas AI automation tools, global e-commerce SaaS leader JST (06687.HK) recorded its largest single-day decline since listing. As of the close on February 5, the stock JST has cumulatively fallen 28.10% since its October 2025 IPO. The market is questioning whether AI will shrink pricing margins for software and destabilize the traditional subscription model, leaving the software industry facing a severe "replacement crisis."
NewTimeSpace News: Luenthai Holdings Limited (00311.HK) issued a profit warning, expecting to record a profit attributable to owners of the company of approximately US$3.8 million to US$4.8 million for the year ended December 31, 2025. This marks a turnaround from a net loss of about US$34 million in the previous fiscal year.
NewTimeSpace News,ZHONGTAIFUTURES issued a profit forecast announcement on February 5. Based on preliminary assessment, the company's net profit attributable to shareholders in 2025 is expected to increase by approximately 1,677% compared with the same period in 2024. The projected performance growth is mainly driven by the company's efforts in improving operational quality and efficiency, as well as the low base in the corresponding period of 2024.
NewTimeSpace News,HENLIUS announced in an announcement on February 5 that it has entered into a license agreement with Eisai, a listed Japanese pharmaceutical company, authorizing Eisai to develop, manufacture and commercialize Hansoh® (Serplulimab Injection) for the treatment of oncology indications in Japan.
NewTimeSpace News, EPRINT GROUP announced on February 5 that Ms. Liang Yanyi has resigned from the positions of Company Secretary and Authorized Representative, and Ms. Yang Bizhen was appointed to take up both roles on the same day.
Since its listing in December 2025, CiDi Inc. (03881.HK) has made significant progress in commercial implementation and industry cooperation. Recently, the company signed multiple strategic partnerships and completed the delivery of 40 autonomous mining trucks in late January, with its deployment scale in Xinjiang exceeding 120 units. However, the capital market response has been lukewarm. Although the company has proposed a "1-for-10" share split to enhance liquidity, as of February 4, 2026, the share price remains below its offer price.
